US and MRI in the evaluation of mammographic BI-RADS 4 and 5 microcalcifications by Hrkac Pustahija, Ana et al.
US and MRI in the evaluation of mammographic BI-RADS 4 and 5 
microcalcifications
Ana Hrkac Pustahija 
Gordana Ivanac 
Boris Brkljacic 
187
Diagn Interv Radiol 2018; 24:187–194
© Turkish Society of Radiology 2018
B R E A S T  I M AG I N G
O R I G I N A L  A R T I C L E 
PURPOSE 
The aim of this study was to assess diagnostic accuracies of ultrasonography (US) and magnetic 
resonance imaging (MRI) in lesions that manifest as mammographic BI-RADS 4 and 5 microcalci-
fications, in the setting of conjoined use of mammography, US, and MRI. 
METHODS
Patients with mammographic BI-RADS 4 or 5 microcalcifications, without additional findings, 
were included in this prospective study. All patients subsequently underwent breast US and 
MRI. Histopathologic diagnosis, obtained by US-guided core-needle biopsy or surgical excision, 
served as a reference standard. Diagnostic accuracies of US and MRI were calculated, and positive 
predictive value for different MRI BI-RADS imaging features were determined. 
RESULTS
The study group consisted of 113 women with 125 areas of suspicious microcalcifications. MRI 
reached sensitivity, specificity, positive predictive value 3 (PPV3), and negative predictive val-
ue (NPV) of 100%, 70.1%, 67.6%, and 100%, respectively. Statistically significant differences in 
MRI morphologic features and kinetic enhancement curves were observed between malignant 
and benign microcalcifications. Sensitivity, specificity, PPV3, and NPV for US were: 85.4%, 66.2%, 
61.2%, and 87.9%. There was statistically significant difference in presentation of malignant and 
benign microcalcifications at US. 
CONCLUSION
In the setting of conjoined use of mammography, US, and MRI, MRI can reliably exclude malig-
nancy in suspicious microcalcifications. Thus, negative MRI findings may influence the decision 
to biopsy the microcalcifications.
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Microcalcifications account for 31% of lesions detected at screening mammography, and are often considered to be an early sign of breast cancer (1, 2). Although easi-ly detectable on mammography, they present a diagnostic challenge. Most mam-
mographic microcalcifications are currently assessed by means of histopathologic workup of 
percutaneous biopsy specimens - histopathologic proof is still considered essential for the 
definitive diagnosis (3–5). However, low specificity of mammography leads to low positive 
predictive value (PPV) of biopsies based on mammographic referral (ranging from 21% to 
42%) (6–9). These data indicate that a large proportion of biopsies yield benign results and, 
therefore, potentially could be avoided (8). Breast Imaging and Reporting System (BI-RADS) is 
aiming to help stratifying the risk of malignancy, but BI-RADS descriptors are often not consis-
tently applied between the readers, and PPV of mammography remains low (6, 10, 11).
Other imaging methods do not have a universally accepted role in the detection and 
characterization of microcalcifications yet (3, 7). Ultrasonography (US), due to considerable 
variations of reported sensitivities, is not considered a reliable tool in the evaluation of mi-
crocalcifications (2, 5, 7, 12–14). Also, the role of magnetic resonance imaging (MRI) is still 
not firmly established. Guidelines of the European Society of Breast Imaging (EUSOBI) claim 
that the negative predictive value (NPV) of MRI (reported to be around 70%) is not sufficient 
to confidently downgrade lesions from suspicious to benign, and alter the decision about bi-
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opsy (3, 4). Since 1996, several studies have 
investigated the diagnostic performance of 
MRI in classification of lesions that appear 
as mammographic microcalcifications, and 
reported results vary substantially (15). 
Approximately 75% of ductal carcino-
ma in situ (DCIS) present with pure mam-
mographic microcalcifications (16). DCIS 
is a disease process that is not well under-
stood, in part because of its heterogeneous 
nature. Many studies aimed to assess prog-
nostic factors to characterize its risk of inva-
sive potential; however, there still remains 
a lack of agreement about its natural his-
tory, workup, and treatment (17–19). While 
there is lack of understanding of DCIS and 
its natural progression, improvements in 
identification of imaging findings related 
to DCIS may be useful. The most common 
mammography appearance for both high-
grade and non–high-grade DCIS is fine 
pleomorphic calcifications, in segmental 
or linear distribution, as reflection of cell 
necrosis and dystrophic calcifications in the 
lumen of the terminal duct (20–23). US fea-
tures of DCIS include ductal abnormalities, 
architectural distortions, and in more than 
70% of DCIS, hyperechoic foci can be de-
tected on US; however, sonography is not 
the imaging modality of choice for diagno-
sis of DCIS (24). MRI is overall more sensitive 
than mammography in the detection of all 
grades of DCIS, with higher sensitivity for 
high-grade and intermediate-grade DCIS 
compared with low-grade DCIS (98%, 91%, 
and 80%, respectively) (20, 25–28). Most 
common MRI presentation of DCIS is non-
mass lesions, with segmental distribution 
and clumped internal enhancement (29). 
MRI features of DCIS are related to specific 
growth pattern within the ducts and typical 
neovascularization: tumor cells can directly 
release angiogenic factors resulting in a rim 
of microvessels adjacent to the basement 
membrane of affected ducts or indirectly 
via recruitment of accessory cells leading 
to diffuse stromal vascularity (30). Addition-
ally, slow enhancement of the actual DCIS 
ducts can also be due to gadolinium enter-
ing the leaky ducts (30, 31). However, MRI 
features of DCIS overlap with some benign 
lesions, such as fibrocystic changes, pseu-
doangiomatous stromal hyperplasia, and 
mastitis, which all can cause false-positive 
MRI findings (30, 32). 
The aim of this study was to assess di-
agnostic accuracies of US and MRI in the 
characterization of lesions that manifest as 
mammographic BI-RADS 4 and 5 microcal-
cifications, in the setting of conjoined use of 
mammography, US, and MRI.
Methods
Study population
Eligible for this prospective study were 
women presenting with mammographic 
BI-RADS 4 and 5 microcalcifications, with-
out associated mammographic findings. 
In further management, patients under-
went breast US, followed by breast MRI. 
The histopathologic diagnosis, obtained 
by US-guided core-needle biopsy (CNB) 
or surgical excision, was set as reference 
standard. High-risk lesions obtained by 
CNB were confirmed by means of surgical 
excision. The results of CNB and surgical 
excision were followed by 1-year follow-up 
with mammography, US and MRI. The study 
design and protocol were reviewed and ap-
proved by the institutional review board. 
All patients signed informed consent after 
the nature of the study had been fully ex-
plained to them.
In a period of three years 164 women 
were enrolled in the study. In the final data 
analysis, 51 women were excluded for the 
following reasons: 15 because mammo-
grams were incomplete (only hard copies 
of film-screen mammograms from out-
side facilities were available to the read-
ers, with MLO and CC projections, without 
spot compression views), 6 patients did 
not undergo US, 4 did not undergo MRI (2 
refused because of claustrophobia, 2 had 
technical contraindications – 1 pacemaker, 
1 ferromagnetic metal foreign bodies), 10 
had no histopathologic diagnosis (did not 
complete workup in our institution), and 
16 cases were lost from follow-up. The final 
study group consisted of 113 patients with 
125 areas of suspicious microcalcifications 
(age range 36–71 years, median 55 years). 
Imaging methods
Mammograms included in the study had 
to be performed using a full field digital 
mammography system (76 were performed 
in our department, using Mammomat No-
vation DR Siemens). Standard mediolateral 
oblique and craniocaudal projections, with 
additional magnification views were per-
formed. In 37 cases where no magnification 
views were available, electronic magnifica-
tion (zooming) of digital mammograms was 
used at the viewing workstation. 
US of the breasts was performed using 
high frequency linear-array broadband 
transducers with a frequency of 9–14 MHz 
and 9–15 MHz (Logiq 9, General Electric 
Healthcare, and Supersonic, Aixplorer® ul-
trasound system, SuperSonic Imagine). US 
examination was directed based on the 
mammographic estimation of the location 
of microcalcifications. US findings of the 
presumed area of mammographic micro-
calcifications were divided into groups of 
1) visible changes, and 2) invisible chang-
es. Visible changes were further subdivid-
ed into: a) microcalcifications (observed as 
hyperechoic dots) within hypoechoic area/
mass or dilated ducts, b) isolated micro-
calcifications, without associated findings, 
c) other parenchymal changes (heteroge-
neous areas without significant hypoechoic 
area/mass or clearly visible microcalcifica-
tions).
Breast MRI was performed at 1.5 T (Mag-
netom Avanto, Siemens). A dedicated 
breast coil was used, with the imaging pro-
tocol consisting of following sequences: 
axial T2-weighted TIRM (TI: 150.0 ms, TR: 
4330.0 ms, TE: 69.0 ms, slice thickness 4 
Main points
• When mammography, US, and MRI are used 
in conjunction for the workup of BI-RADS 4 
and 5 microcalcifications, MRI reaches 100% 
sensitivity, 70.1% specificity, 67.6% positive 
predictive value (PPV3), and 100% negative 
predictive value (NPV). This means that neg-
ative MRI finding in such clinical setting may 
confidently rule out malignancy, and thus, 
influence the decision to perform biopsy of 
microcalcifications.
• When MRI BI-RADS descriptors are applied in 
analysis, microcalcifications present most com-
monly as non-mass lesions, with statistically 
significant difference in presentation of malig-
nant and benign microcalcifications. Highest 
risk of malignancy is found for segmental dis-
tribution and clumped internal enhancement.
• US has shown clinically unacceptable values 
for test performance as a method for ruling out 
malignancy, with 100% sensitivity, 66.2% spec-
ificity, 61.2% PPV3, and 87.9% NPV. 
• In cases when microcalcifications are visu-
alized with US (78.4% of cases in our study), 
there is statistically different presentation be-
tween malignant and benign microcalcifica-
tions. Thus, recognizing specific patterns of US 
presentation of malignant and benign micro-
calcifications may add additional value to the 
MRI performance. US finding of “hyperechoic 
dots within hypoechoic mass, area or dilated 
ducts” is most commonly related to malignan-
cy, while finding of “isolated microcalcifica-
tions within normal breast tissue” is seen only 
in benign cases.
mm, 320 mm field of view [FoV]), sagittal 
T2-weighted fast spin echo with fat satura-
tion (TR: 7300.0 ms, TE: 113.0 ms, slice thick-
ness 4 mm, 180 mm FoV), axial T2-weighted 
turbo spin echo (TR: 4000.0 ms, TE: 60.0 ms, 
slice thickness 4 mm, 380 mm FoV), axial 
T1-weighted three-dimensional (3D) gra-
dient echo with fat saturation (TR: 4.3 ms, 
TE: 1.3 ms, slice thickness 0.8 mm, 340 mm 
FoV). Axial T1-weighted 3D gradient echo 
without fat saturation (TR: 16.0 ms, TE: 4.8 
ms, slice thickness 2 mm, 320 mm FoV) be-
fore contrast administration and dynamic 
3D axial T1-weighted gradient echo without 
fat saturation five times after the injection 
of the bolus of 0.1 mmol/kg of paramagnet-
ic contrast agent (gadoterate meglumine, 
Dotarem ®) for both breasts were collected. 
Unenhanced images were then subtracted 
from the contrast- enhanced images on a 
pixel-by-pixel basis. Multiplanar reformat-
ting (MPR) reconstructions and maximum 
intensity projection (MIP) reconstructions 
were performed, with dynamic (kinetic) 
time-intensity curves generated in the se-
lected region of interest (ROI). 
CNB was performed after MRI, under US 
guidance, using a 14-gauge biopsy device 
(Monopty, Bard), with multiple passes per 
lesion. Mammography of the specimen was 
performed in order to confirm the presence 
of microcalcifications in the specimen. In 
patients with surgical excision of lesions, 
wire localization of microcalcifications was 
performed under US and correct position 
was confirmed by mammography. For so-
nographically invisible lesions, mammogra-
phy guidance of biopsy, with a fenestrated 
compression paddle with alpha-numeric 
grid, was used. 
Statistical analysis
Imaging findings were analyzed and re-
ported using BI-RADS descriptors (10, 11). 
To calculate diagnostic accuracies of imag-
ing methods, findings were dichotomized: 
negative examinations were defined as ex-
aminations with BI-RADS final assessment 
category of 1–3, while positive examina-
tions were defined as examinations with 
final assessment category of 4 and 5. Pos-
itive predictive value (PPV) was calculated 
as the number of detected cancers per 
positive examinations. The positive predic-
tive value category 3 (PPV3) defined as per 
BI-RADS Atlas 5th edition is the rate of de-
tected cancers (true positive) divided by all 
patients in whom biopsy was performed 
(true positive and false positive) (11). Since 
all our patients had biopsy performed af-
ter imaging work-up was finished, PPV3 
was calculated in all cases. Sensitivity was 
calculated as the number of positive ex-
aminations for which there was a tissue 
diagnosis of cancer, divided by all cancers 
present in the study group. Specificity was 
calculated as the number of negative ex-
aminations for which there was no tissue 
diagnosis of cancer, divided by all exam-
inations for which there was no tissue di-
agnosis of cancer. Negative predictive val-
ue (NPV) was calculated as the number of 
negative examinations for which there was 
no tissue diagnosis of cancer, divided by all 
negative examinations.
All clinical and imaging data were avail-
able to the reading radiologist, and findings 
were presented and discussed at the mul-
tidisciplinary breast team meetings. Mam-
mographic and MRI examinations were 
interpreted by one of three co-authors (ra-
diologists with 10–22 years of experience in 
breast imaging). Screening mammograms 
were evaluated by two radiologists inde-
pendently and diagnostic mammograms 
by one. US exams and CNB were performed 
by a single examiner with 22 years of expe-
rience in breast imaging.
Data were analyzed using the Statisti-
cal Package for Social Sciences 16.0 (SPSS 
Inc.). Chi square, Fisher’s exact test and the 
Mann-Whitney U test were used for com-
parison of the groups, with two-tailed P 
value less than 0.05 considered statistically 
significant. Study sample size requirements 
were calculated based on a clinically ac-
ceptable degree of precision, at the esti-
mated prevalence of disease in the target 
population, and at the hypothesized values 
of sensitivity, specificity, and predictive val-
ues; thus, at the estimated prevalence of 
the disease in the target population of 40% 
and at the hypothesized value of sensitivity 
equal to 85% the calculated required sam-
ple size was 123, and at the hypothesized 
value of specificity equal to 75% the calcu-
lated required sample size was 120, based 
on a 95% confidence interval of hypothe-
sized sensitivity and specificity (33).
Results 
Histologic diagnoses are presented in 
Table 1. Prevalence of malignancy in our 
study group was 38.4% (48/125). As shown 
in Table 1, pure DCIS comprised 52.1% of 
malignant cases, microinvasive lesions fur-
ther 12.5%, and invasive lesions 35.4%. The 
details of other histopathologic findings 
can be found in Table 1.
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Table 1. Histopathologic diagnoses of mammographic BI-RADS 4 and 5 microcalcifications in our 
study
Histologic diagnosis No. of cases (%)
Malignant (n=48, 38.4%)
DCIS 25 (52.1)
IDC 21 (43.8)
IDC+DCIS 7 
DC mic 6
IDC 8
ILC 2 (4.2)
Total 48 (100)
Benign (n=77, 61.6%)
Sclerosing adenosis 16 (20.8)
Flat epithelial atypia 6 (7.8)
Complex sclerosing adenosis 4 (5.2)
LCIS 4 (5.2)
ADH 2 (2.6)
Intraductal papilloma 2 (2.6)
Other benign changes- B2 43 (55.8) 
Total 77 (100)
DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; DC mic, microinvasive ductal carcinoma; ILC, 
invasive lobular carcinoma; LCIS, lobular carcinoma in situ; ADH, atypical ductal hyperplasia.
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Mammography as indicator for biopsy 
yielded PPV3 of 38.4%. Separately, mam-
mographic BI-RADS 4 category yielded 
PPV3 of 34.5% (40/116 malignant micro-
calcifications), and BI-RADS 5 had PPV3 of 
88.9% (8/9 malignant). 
Results of US in workup of microcalcifica-
tions are shown in Tables 2 and 3. Sensitiv-
ity, specificity, PPV3, and NPV for US were: 
85.4% (95% CI, 72.2– 93.9), 66.2% (95% CI, 
54.5– 76.6), 61.2% (95% CI, 48.5–72.8), and 
87.9% (95% CI, 76.7– 95.0). Overall, chang-
es associated with microcalcifications were 
seen on US in 78.4% of cases. Malignant 
microcalcifications were more likely to be 
visible on US (85.4% of cases) compared to 
benign ones (74%). However, difference in 
visibility between malignant and benign 
lesions did not reach statistical significance 
(P = 0.18). As summarized in Table 3, ma-
lignant and benign microcalcifications pre-
sented differently on US, with statistically 
significant difference. Finding “hyperechoic 
dots within hypoechoic mass, area or dilat-
ed ducts” was most commonly related to 
malignancy, with the highest PPV3 (67.3%). 
Isolated microcalcifications within normal 
breast tissue were seen only in benign 
cases, with NPV of 100%. High-risk lesions 
comprised a higher portion of false positive 
findings (44.4%, 8/18). Among false nega-
tive findings of US, 71.4% (5/7) were pure 
DCIS lesions, while the rest (28.6%, 2/7) 
were invasive lobular carcinoma. 
Microcalcifications visible on US had 
larger mammographic diameter compared 
with those invisible on US, with statistical-
ly significant difference (median of mam-
Table 2. Correlation of sonographic visibility of microcalcifications with histologic findings, mam-
mographic diameter and mammographic BI-RADS category
US visible, n (%) US invisible, n (%) P
Histologic findings 0.18
Malignant disease 41 (85.4) 7 (14.6)
Benign disease 57 (74.0) 20 (26.0)
Total 98 (78.4) 27 (21.6)
Mammographic size of cluster (mm), median 
(range)
29 (5–85) 20 (6–58) 0.037
Mammographic BI-RADS category 0.20
BI-RADS 4 89 (76.7) 27 (23.3)
BI-RADS 5 9 (100) 0 (0)
BI-RADS, breast imaging-reporting and data system.
Table 3. US features of mammographic BI-RADS 4 and 5 microcalcifications
Malignant Benign Total (%) PPV3
US findings*
Microcalcifications within hypoechoic mass, area 
or dilated ducts
35 17 52 (41.6) 67.3%
Isolated microcalcifications 0 9 9 (7.2) 0
Heterogeneous regions without mass or clearly 
visible microcalcifications
6 31 37 (29.6) 16.2%
Negative (US invisible microcalcifications) 7 20 27 (21.6) 25.9%
Total 48 77 125 (100)
US BI-RADS 1–3 7 51 58 (46.4)
US BI-RADS 4–5 41 26 67 (53.6)
BI-RADS, breast imaging-reporting and data system; US, ultrasonography; PPV3, positive predictive value calcu-
lated based on performed biopsy. 
*US findings of microcalcifications were significantly different between benign and malignant cases (P < 0.001).
Figure 1. a, b. Mammography, mediolateral 
oblique (a) and craniocaudal (b) projections: 
fine pleomorphic and linear branching 
microcalcifications, in segmental distribution, 
in the upper outer quadrant of the right breast. 
Multiple lobulated densities are seen in all 
quadrants.
b
a
mographic diameters: 29 mm vs. 20 mm; P 
= 0.037) (Table 2).
Detailed MRI features of microcalcifica-
tions are presented in Table 4. Sensitivity, 
specificity, PPV3, and NPV of MRI were 100% 
(95% CI, 92.6–100), 70.1% (95% CI, 58.6–
80.0), 67.6% (95% CI, 55.5–78.2), and 100% 
(95% CI, 93.4–100). Overall, non-mass lesion 
enhancement was the most common pre-
sentation of microcalcifications (58.4% of all 
cases). We compared diagnostic accuracies 
separately for masses and non-mass lesions 
to test the influence of lesion type on di-
agnostic capabilities of MRI. There was no 
statistically significant association between 
lesion type and diagnostic accuracy (P = 
0.59): sensitivity, specificity, PPV3, and NPV 
for masses were 100% (95% CI, 79.4–100), 
50% (95% CI, 15.7–84.3), 80% (95% CI, 56.3–
94.3), and 100% (95% CI, 39.8–100), and for 
non-mass lesions 100% (95% CI, 89.1–100), 
53.7% (95% CI, 37.4–69.4), 62.6% (95% CI, 
48.0–75.9), and 100% (95% CI, 84.6–100). 
However, masses had higher probability to 
be malignant (PPV3, 66.7%), compared with 
non-mass lesions (PPV3, 43.8%). 
Figs. 1–3 show representative cases of 
conjoined mammography, US, and MRI 
workup of microcalcifications. Histologic 
diagnosis after second-look US-guided CNB 
was atypical ductal hyperplasia. Wide surgi-
cal excision was recommended because of 
highly suspicious findings of MRI. Diagnosis 
after excision was multiple foci of DCIS, and 
because of widespread area of non-mass 
enhancement seen on MRI, mastectomy 
was performed. Final diagnosis was micro-
invasive ductal carcinoma. 
Discussion
In this study, consecutive enrollment of 
mammography, US, and MRI in the work-
up of microcalcifications resulted in MRI 
sensitivity of 100%, with NPV of 100%. Al-
though estimated PPV3 for the MRI was 
only moderate (67.6%), it is still a signifi-
cant improvement compared with PPV3 of 
mammography alone (which was 38.4% in 
our study, and according to literature rang-
es from 21% to 42%) (6–9). Such conjoined 
approach, with US and MRI used in addition 
to mammography in workup of microcalci-
fications, has not been so far published in 
the literature (3, 4, 31, 34–43). 
Concerning the role of US in the assess-
ment of microcalcifications, in our study 
78.4% of microcalcifications were identified 
at US. Those rates are very heterogeneous 
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Table 4. MRI features of pure microcalcifications in correlation to histopathology
Malignant Benign Total (%) PPV3 P
MRI BI-RADS category
MRI BI-RADS 1 0 0 0 (0) 0
MRI BI-RADS 2 0 21 21 (16.8) 0
MRI BI-RADS 3 0 33 33 (26.4) 0
MRI BI-RADS 4 8 21 29 (23.2) 27.6%
MRI BI-RADS 5 40 2 42 (33.6) 95.2%
Total 48 77 125 (100)
Morphology <0.001
Mass 16 8 24 (19.2) 66.7%
Non-mass enhancement 32 41 73 (58.4) 43.8%
Focus 0 28 28 (22.4) 0
Total 48 77 125 (100)
Kinetic curve type <0.001
Wash-out 29 8 37 (38.1) 78.4%
Plateau 17 17 34 (35.1) 50.0%
Persistent 2 24 26 (26.8) 7.7%
Total 48 49 97 (100)
Mass shape 0.16
Round 3 2 5 (20.8) 60.0%
Oval 3 3 6 (25) 50.0%
Lobulated 1 2 3 (12.5) 33.3%
Irregular 9 1 10 (41.7) 90.0%
Total 16 8 24 (100)
Mass margin 0.007
Smooth 0 4 4 (16.7) 0
Irregular 12 4 16 (66.7) 75.0%
Spiculated 4 0 4 (16.7) 100.0%
Total 16 8 24 (100)
Mass enhancement <0.001
Homogeneous 0 4 4 (16.7) 0
Heterogeneous 16 2 18 (75.0) 88.9%
Dark internal septa 0 2 2 (8.3) 0
Enhancing internal 
septa
0 0 0 (0) 0
Rim 0 0 0 (0) 0
Central 0 0 0 (0) 0
Total 16 8 24 (100)
Non-mass distribution <0.001
Focal 0 19 19 (26) 0
Linear 1 3 4 (5.5) 25.0%
Ductal 2 2 4 (5.5) 50.0%
Segmental 19 9 28 (38.4) 67.9%
Regional 10 8 18 (24.7) 55.6%
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in the literature, and vary from 23% to 97% 
(2, 5, 7, 12, 44, 45). But, we have found that, 
when microcalcifications are visualized with 
US, there is a statistically different presen-
tation between malignant and benign mi-
crocalcifications. US finding of “hyperechoic 
dots within hypoechoic mass, area or dilated 
ducts” was most commonly related to malig-
nancy, while finding of “isolated microcalci-
fications within normal breast tissue” was 
seen only in benign cases. Also, malignant 
microcalcifications in our study were more 
commonly visualized than benign (85.4% 
vs. 74%), which is in accordance with other 
studies (2, 14, 46). This permits us to presume 
that recognition of such different patterns of 
sonographic presentation of microcalcifica-
tions may add additional value when per-
forming MRI after US, and thus improve MRI 
performance for microcalcifications. 
Regarding different MRI BI-RADS imaging 
features, we noticed that lesion type (mass 
vs. non-mass) did not influence significantly 
on the diagnostic accuracy of MRI, with sim-
ilar sensitivity and specificity for both sub-
groups, which is opposite to the findings so 
far published in the literature. To our knowl-
edge, there are only two previous studies 
which analyzed individual MRI BI-RADS 
descriptors associated with malignancy in 
cases of microcalcifications, and our results 
are in agreement with earlier published data 
(31, 41). However, no prior study assessed 
PPVs of different MRI features in the workup 
of microcalcifications. As shown in Table 4, 
MRI morphologic features of masses with 
highest PPV3 in our study were irregular 
shape, spiculated margin, and heteroge-
neous internal enhancement. For the non-
mass enhancement lesions, malignancy was 
typically represented by segmental distribu-
tion and clumped internal enhancement. 
Wash-out kinetic dynamic enhancement 
curve was highly indicative of malignancy, 
both for masses and non-mass lesions. 
We analyzed earlier reports on diag-
nostic performances of MRI in workup of 
microcalcifications (3, 4, 31, 34–43). Those 
reports vary substantially in methodology 
and results, with sensitivities ranging from 
45% to 100%, and specificities from 51% to 
100%. Recently, a review and meta-analysis 
study was published by Bennani-Baiti and 
Baltzer (15), aiming to clarify the role of MRI 
in assessment of mammographic BI-RADS 
3–5 microcalcifications. Twenty studies met 
their inclusion criteria, with 1843 lesions 
and a mean prevalence of malignancy of 
40.6%. It is interesting that seven of those 
20 studies were published after 2014, while 
the oldest study dated from 1996. Authors 
revealed pooled sensitivity and specificity of 
92% and 82% for BI-RADS 4 lesions, 95% and 
66% for BI-RADS 5 lesions, and 57% and 32% 
for BI-RADS 3 lesions. Their conclusion was 
that MRI is not recommended for diagno-
sis of malignancy in BI-RADS 3 and 5 mam-
mographic microcalcifications but can be 
considered for BI-RADS 4 microcalcifications.
We analyzed potential biases which 
might have influenced our results. As 
shown in our study, pure microcalcifica-
tions present most commonly as non-
mass lesions (Table 4). Non-mass lesions 
are well recognized as the problem mak-
ers in breast MRI: most readers have prob-
lems in the interpretation of non-mass le-
sions, while inexperienced readers’ ability 
to differentiate benign from malignant 
non-mass lesion can be close to guessing 
(6). This points out importance of expe-
rience in cases of microcalcifications. In 
our study only experienced readers were 
included, but we did not perform interob-
Table 4. MRI features of pure microcalcifications in correlation to histopathology (cont’d)
Multiple regions 0 0 0 (0) 0
Diffuse 0 0 0 (0) 0
Total 32 41 73 (100)
Non-mass internal enhancement <0.001
Homogeneous 0 1 1 (1.4) 0
Heterogeneous 0 14 14 (19.2) 0
Stippled 2 16 18 (24.7) 11.1%
Clumped 30 10 40 (54.8) 75.0%
Reticular 0 0 0 (0) 0
Total 32 41 73 (100)
MRI, magnetic resonance imaging; BI-RADS, breast imaging-reporting and data system; PPV3, positive predictive 
value calculated based on performed biopsy.
Figure 2. Ultrasound: microcalcifications were in B-mode visible as hyperechoic dots (yellow arrows) 
surrounded by heterogeneous irregular area. Multiple large cysts in all quadrants (asterisk) correlated 
with lobulated densities visible on mammography. Circles with “x” and “+” marks remained from 
elastography measurements, which were not analyzed in this study.
server variability analysis, which prevents 
us from drawing a conclusion about the 
influence of readers’ experience on re-
sults. Next potential bias is patient selec-
tion procedure. There are some reports 
that performances of MRI in microcalcifi-
cations are somewhat better for invasive 
lesions (15). Prevalence of malignancy in 
our study was 38.4%, which is close to av-
erage published rates (around 40%), and 
declines one of the possible patient se-
lection biases. Prevalence of DCIS among 
malignant lesions is also recognized as a 
potential cause of lower specificity of MRI 
in microcalcifications. In the review study 
published by Bennani-Baiti and Baltz-
er (15), among 1843 lesions, there were 
106 false-negative findings (5.8%), 68 of 
which (64.2%) were DCIS only. When DCIS 
was excluded, the pooled negative pre-
dictive value of breast MRI to rule out in-
vasive or microinvasive cancer was found 
to be significantly higher, reaching 99%. 
DCIS comprised 52.1% of our malignant 
cases (Table 1) and was the major cause 
of false negative findings of US in our 
study (71.4%). But, as mentioned earlier, 
we did not have false negative MRI find-
ings, so we cannot assess the influence of 
DCIS on sensitivity of MRI in our study. 
There are several limitations to our study. 
First, vacuum-assisted biopsy is considered 
the method of choice in cases of pure mi-
crocalcifications. We used US-guided CNB 
due to organization of work in our facility 
but tried to address this issue by having a 
single highly experienced radiologist per-
form all US-guided CNB (22 years of expe-
rience in breast imaging, including US). 
Also, mammography of biopsy specimens 
was performed to confirm the presence 
of microcalcifications. Second, we did not 
perform interobserver variability tests 
for MRI results, which leaves us without 
quantitative analysis of the exact effect 
of experience on diagnostic accuracy of a 
method. Also, we did not perform blinded 
MRI reading (without knowledge of prior 
US findings). Therefore, we cannot com-
pare blinded and non-blinded results, and 
thus cannot assess exact influence of per-
forming US prior to MRI on final results of 
MRI. We can just assess combined methods 
diagnostic accuracy (US + MRI), presented 
through diagnostic accuracy achieved with 
MRI. We did not perform detailed analysis 
on different subgroups of cases (such as US 
or MRI features for different histologic diag-
noses, for different type of microcalcifica-
tions according to mammographic BI-RADS 
descriptors, for breast density, patients, he-
reditary risk for breast carcinoma, correla-
tion of microcalcifications area diameter to 
MRI findings), which prevents us from ana-
lyzing the influence of those covariates on 
our results. Finally, we did not analyze the 
number of false positive findings found on 
MRI in the contralateral breast or in other 
parts of the same breast.
In conclusion, the aim of our study was 
to test the suitability of conjoined use of 
mammography, US, and MRI in the evalu-
ation of mammographic BI-RADS 4 and 5 
microcalcifications. In such settings, MRI 
reaches NPV of 100%, which supports the 
application of MRI for exclusion of malig-
nancy, and suggests that negative MRI may 
influence the decision to biopsy microcalci-
fications. However, further work with larg-
er number of cases is needed to validate 
our results. There is statistically significant 
difference in presentation between malig-
nant and benign microcalcifications when 
MRI BI-RADS descriptors are applied in the 
analysis. Microcalcifications appear most 
commonly as non-mass lesions, which is 
important to keep in mind when MRI is 
used for the workup of microcalcifications, 
since non-mass lesions are the major cause 
of possible false negative findings of MRI. 
On the other hand, US cannot reliably ex-
clude malignancy nor decline the need for 
biopsy. However, when microcalcifications 
are visualized with US prior to MRI, recog-
nition of a different pattern of sonographic 
presentation of malignant and benign mi-
crocalcifications may add additional value 
to the performance of MRI.  
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